JP2021501592A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501592A5 JP2021501592A5 JP2020524490A JP2020524490A JP2021501592A5 JP 2021501592 A5 JP2021501592 A5 JP 2021501592A5 JP 2020524490 A JP2020524490 A JP 2020524490A JP 2020524490 A JP2020524490 A JP 2020524490A JP 2021501592 A5 JP2021501592 A5 JP 2021501592A5
- Authority
- JP
- Japan
- Prior art keywords
- probe
- absence
- immunotherapy
- chromosomal
- probe sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000523 sample Substances 0.000 claims 18
- 238000000034 method Methods 0.000 claims 16
- 230000003993 interaction Effects 0.000 claims 10
- 230000002759 chromosomal effect Effects 0.000 claims 9
- 238000009169 immunotherapy Methods 0.000 claims 7
- 108020004414 DNA Proteins 0.000 claims 6
- 210000000349 chromosome Anatomy 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 238000003753 real-time PCR Methods 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000012270 PD-1 inhibitor Substances 0.000 claims 1
- 239000012668 PD-1-inhibitor Substances 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 230000001024 immunotherapeutic effect Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 238000010791 quenching Methods 0.000 claims 1
- 230000000171 quenching effect Effects 0.000 claims 1
- 238000011895 specific detection Methods 0.000 claims 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023060384A JP7631400B2 (ja) | 2017-11-03 | 2023-04-03 | 遺伝子調節 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762581287P | 2017-11-03 | 2017-11-03 | |
| US62/581,287 | 2017-11-03 | ||
| GBPCT/GB2018/052818 | 2018-10-03 | ||
| GB2018052818 | 2018-10-03 | ||
| PCT/GB2018/053196 WO2019086898A2 (en) | 2017-11-03 | 2018-11-02 | Genetic regulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060384A Division JP7631400B2 (ja) | 2017-11-03 | 2023-04-03 | 遺伝子調節 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021501592A JP2021501592A (ja) | 2021-01-21 |
| JP2021501592A5 true JP2021501592A5 (enExample) | 2021-12-09 |
Family
ID=64661410
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524490A Pending JP2021501592A (ja) | 2017-11-03 | 2018-11-02 | 遺伝子調節 |
| JP2023060384A Active JP7631400B2 (ja) | 2017-11-03 | 2023-04-03 | 遺伝子調節 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060384A Active JP7631400B2 (ja) | 2017-11-03 | 2023-04-03 | 遺伝子調節 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11840737B2 (enExample) |
| EP (1) | EP3704274B1 (enExample) |
| JP (2) | JP2021501592A (enExample) |
| KR (1) | KR102885025B1 (enExample) |
| CN (1) | CN111511930B (enExample) |
| AU (1) | AU2018361833B2 (enExample) |
| CA (1) | CA3078675A1 (enExample) |
| ES (1) | ES2987603T3 (enExample) |
| HU (1) | HUE066292T2 (enExample) |
| MY (1) | MY199800A (enExample) |
| PL (1) | PL3704274T3 (enExample) |
| SG (1) | SG11202003233YA (enExample) |
| WO (1) | WO2019086898A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3152645A1 (en) * | 2019-09-11 | 2021-03-18 | Oxford BioDynamics PLC | Diagnostic chromosome marker |
| EP4121964A1 (en) * | 2020-03-17 | 2023-01-25 | Regeneron Pharmaceuticals, Inc. | Methods and systems for determining responders to treatment |
| GB202008269D0 (en) * | 2020-06-02 | 2020-07-15 | Oxford Biodynamics Ltd | Detecting a chromosome marker |
| GB202016176D0 (en) * | 2020-10-12 | 2020-11-25 | Oxford BioDynamics PLC | Disease marker |
| TW202302862A (zh) * | 2021-03-04 | 2023-01-16 | 英商牛津生物力學公眾有限公司 | 染色體交互作用標記物 |
| WO2025215189A1 (en) * | 2024-04-12 | 2025-10-16 | Oxford BioDynamics PLC | Chromosome marker test |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036993A1 (es) * | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| GB0603251D0 (en) | 2006-02-17 | 2006-03-29 | Isis Innovation | DNA conformation |
| AU2008204338B2 (en) | 2007-01-11 | 2014-03-06 | Erasmus University Medical Center | Circular chromosome conformation capture (4C) |
| WO2009051268A2 (en) | 2007-10-15 | 2009-04-23 | Takeda Pharmaceutical Company Limited | Preventive/remedy for cancer |
| GB0810051D0 (en) | 2008-06-02 | 2008-07-09 | Oxford Biodynamics Ltd | Method of diagnosis |
| BRPI1007093A2 (pt) | 2009-05-12 | 2017-06-06 | Koninl Philips Electronics Nv | fosfodiesterase 4d7 uso de pde4d7; composição metodo, metodo de aquisição de dados imunoensaio para detectar diagnosticar, monitorar ou prognosticar cancer de prostata ou para diagnosticar, detectar monitorar ou prognosticar progressao do cancer |
| EP3004877A4 (en) * | 2013-06-06 | 2017-04-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
| WO2015077414A1 (en) | 2013-11-20 | 2015-05-28 | Dana-Farber Cancer Institute, Inc. | Kynurenine pathway biomarkers predictive of anti-immune checkpoint inhibitor response |
| JP2018518203A (ja) * | 2015-06-24 | 2018-07-12 | オックスフォード バイオダイナミックス リミテッド | エピジェネティックな染色体相互作用 |
-
2018
- 2018-11-02 HU HUE18815789A patent/HUE066292T2/hu unknown
- 2018-11-02 WO PCT/GB2018/053196 patent/WO2019086898A2/en not_active Ceased
- 2018-11-02 AU AU2018361833A patent/AU2018361833B2/en active Active
- 2018-11-02 US US16/760,541 patent/US11840737B2/en active Active
- 2018-11-02 CA CA3078675A patent/CA3078675A1/en active Pending
- 2018-11-02 KR KR1020207012736A patent/KR102885025B1/ko active Active
- 2018-11-02 ES ES18815789T patent/ES2987603T3/es active Active
- 2018-11-02 CN CN201880083380.6A patent/CN111511930B/zh active Active
- 2018-11-02 EP EP18815789.5A patent/EP3704274B1/en active Active
- 2018-11-02 MY MYPI2020002029A patent/MY199800A/en unknown
- 2018-11-02 JP JP2020524490A patent/JP2021501592A/ja active Pending
- 2018-11-02 PL PL18815789.5T patent/PL3704274T3/pl unknown
- 2018-11-02 SG SG11202003233YA patent/SG11202003233YA/en unknown
-
2023
- 2023-04-03 JP JP2023060384A patent/JP7631400B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501592A5 (enExample) | ||
| JP2019533432A5 (enExample) | ||
| JP2018529326A5 (enExample) | ||
| JP2024114703A5 (enExample) | ||
| JP2017510244A5 (enExample) | ||
| JP2014509862A5 (enExample) | ||
| US12018317B2 (en) | High throughput oil-emulsion synthesis of bowtie barcodes for paired mRNA capture and sequencing from individual cells | |
| WO2015112949A2 (en) | Isothermal methods and related compositions for preparing nucleic acids | |
| KR20180043401A (ko) | WT1 mRNA의 발현량 정량 방법 | |
| JP2020537514A5 (enExample) | ||
| JP2007525224A (ja) | 核酸複合体 | |
| JP2020524495A5 (enExample) | ||
| IL304071A (en) | Chromosome interactions | |
| JP6495333B2 (ja) | 一塩基多型検出用オリゴヌクレオチドプローブ及び一塩基多型検出方法 | |
| JP2016214086A (ja) | Ｅｇｆｒ遺伝子の変異検出方法及びキット | |
| Machnik et al. | A peptide nucleic acid (PNA)-mediated polymerase chain reaction clamping allows the selective inhibition of the ERVWE1 gene amplification | |
| CN106967833B (zh) | 用于二倍体a基因组棉种和/或四倍体棉种鉴定的引物及其pcr鉴定方法 | |
| GB2597895A (en) | Chromosome conformation markers of prostate cancer and lymphoma | |
| JPWO2016194552A1 (ja) | 複数の標的核酸の検出キット及びそれを用いる検出方法 | |
| JP2018504908A (ja) | 相補的塩基配列ないしはミス−マッチされた塩基を含む相補的な塩基配列と連結されたｐｃｒプライマー及びそれを用いた核酸増幅方法 | |
| CN111004805A (zh) | T细胞免疫检查点pd-l1的适配体筛选、鉴定方法及抗肿瘤应用 | |
| KR101274118B1 (ko) | 리스테리아 모노사이토제네스 생균의 표면에 특이적으로 결합하는 ｄｎａ 앱타머 및 이의 용도 | |
| CN107034275A (zh) | 一种与脑卒中发生发展相关的基因的用途 | |
| JP2020178681A (ja) | 核酸検出方法、及び試薬キット | |
| KR101651212B1 (ko) | 쉬겔라 소네이 생균의 표면에 특이적으로 결합하는 dna 앱타머 및 이의 용도 |